Back
Leukotriene D4 inhalation challenge for predicting short-term efficacy of montelukast: a pilot study.
WJ. Guan, X. Shi, JP. Zheng, Y. Gao, CY. Jiang, YQ. Xie, QX. Liu, Z. Zhu, E. Guo, JY. An, XX. Yu, WT. Liu, NS. Zhong
Clin Respir J 2015 Jan;9(1):111-20.
PubMed: 24506412
Abstract
The convenient measure to predict efficacy of leukotriene receptor antagonist is lacking. To determine if leukotriene D4 inhalation challenge predicts short-term efficacy of montelukast in asthma. In this open-labelled 28-day trial, 45 patients with asthma were allocated to leukotriene-sensitive and leukotriene-insensitive group to receive montelukast monotherapy (10 mg, once daily) based on the positive threshold of leukotriene D4 inhalation challenge test (4.800 nmol). Miscellaneous measurements comprised fractional exhaled nitric oxide, methacholine inhalation challenge, Asthma Control Test and Asthma Quality of Life Questionnaire. Peak expiratory flow was self-monitored throughout the treatment. End point assessments were performed 3 to 5 days after montelukast withdrawal. Twenty-three patients in leukotriene-sensitive group and 10 leukotriene-insensitive group completed the study. Both groups differed neither in 28-day peak expiratory flow rate nor in maximal weekly peak expiratory flow (both P > 0.05). However, minimal weekly peak expiratory flow was significantly higher in leukotriene-insensitive group throughout the treatment course (all P 0.05). Both groups did not differ statistically in the post-treatment improvement in forced expiratory volume in 1 s (FEV1 ) predicted% prior to inhalation challenge, fractional exhaled nitric oxide or the airway responsiveness to leukotriene D4 or methacholine (all P > 0.05). There was a marked increase in Asthma Control Test score and the symptom score of Asthma Quality of Life Questionnaire in both groups (both P
Associated compounds:
Compound Name
with link to compound page |
Structure | Number of references |
---|---|---|
Leukotriene D4 | 37 |